p97/VCP ATPase inhibitor (PDE6 off-target)

Ph. I in cancer (discont., dyschromatopsia)

from HTS of NIH compound library

J. Pharmacol. Exp. Ther., Apr. 30, 2021

Cleave Therapeutics, San Francisco, CA


The Cleave Therapeutics p97 (VCP) inhibitor, CB-5083, was a Ph. I clinical candidate for cancer that was terminated due to vision side effects including causing patients to see unusual colors…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: